Retatrutide is a novel triple agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors. By activating these three key receptors, Retatrutide exerts a powerful and synergistic effect on metabolic regulation. It enhances insulin secretion, reduces appetite, promotes fat metabolism, and increases energy expenditure. This multi-receptor action leads to significant improvements in both blood glucose control and body weight reduction. Clinical trials have shown that Retatrutide can lead to substantial weight loss and improved glycemic control, making it a promising therapeutic candidate for obesity and type 2 diabetes. As a synthetic peptide administered via weekly subcutaneous injection.
| Product Name | Retatrutide Peptide |
| Shelf Life | 2 Years |
| Form | Peptide |
| Indication | Weight Loss |
| Dosage | 1mg~12mg/week |
| Active Ingredient | Retatrutide |
| Storage Conditions | Store At 2-25°C |
| Packaging | 10mg/vial, 15mg/vial, 20mg/vial, 30mg/vial, 40mg/vial |
1. For blood sugar control in adults with type 2 diabetes.
2. Improve long-term weight management in overweight patients with adult obesity or with at least one weight-related comorbidity.
For high value products, please select air shipping and express delivery for safety.
